Genetic GLP-1 Resistance Could Explain Uneven Ozempic Responses
TL;DR Summary
Stanford-led research links PAM gene variants to GLP-1 resistance, where higher GLP-1 levels do not translate to better blood-sugar control, helping explain why roughly 10% of people respond poorly to Ozempic- and Wegovy-like drugs; the findings point toward precision medicine and may favor longer-acting GLP-1 therapies or alternatives for those with the variants.
- Why Ozempic doesn’t work for everyone: Scientists just found a hidden reason ScienceDaily
- Genetic predictors of GLP1 receptor agonist weight loss and side effects Nature
- Weight-loss drugs: Who benefits most and why? BBC
- Genes May Predict How Much You’ll Lose on a Weight-Loss Drug WSJ
- Genetic variants may reduce effectiveness of popular diabetes drugs News-Medical
Reading Insights
Total Reads
0
Unique Readers
15
Time Saved
10 min
vs 11 min read
Condensed
98%
2,130 → 53 words
Want the full story? Read the original article
Read on ScienceDaily